Disease Burden, Characteristics, and Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection in Hong Kong

• Published in: Asia-Pacific journal of public health 2017-07, Vol.29 (5), p.451-461
• Main Authors: You, Joyce H. S., Choi, Kin-wing, Wong, Tin-yau, Ip, Margaret, Ming, Wai-kit, Wong, Rity Yee-kwan, Chan, Sze-ngai, Tse, Hoi-tung, Chau, Carrie T. S., Lee, Nelson L. S.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Bacteremia - economics; Bacteremia - microbiology; Bacteremia - mortality; Cost of Illness; Cross Infection - economics; Cross Infection - microbiology; Cross Infection - mortality; Female; Hong Kong - epidemiology; Hospital Costs - statistics & numerical data; Hospitals, Public - economics; Humans; Male; Methicillin-Resistant Staphylococcus aureus - isolation & purification; Middle Aged; Original Article; Retrospective Studies; Staphylococcal Infections - economics; Staphylococcal Infections - microbiology; Staphylococcal Infections - mortality; Young Adult
• ISSN: 1010-5395; 1941-2479
• DOI: 10.1177/1010539517717365

We aimed to describe disease burden, characteristics, and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) in Hong Kong. A retrospective, observational study was conducted in 26 Hong Kong public hospitals between January 2010 and December 2012. The primary outcome measures were 30-day mortality rate and infection-related hospital cost. Of 1133 patients reviewed, 727 (64.17%) were male, 1075 (94.88%) had health care–associated community-onset and 44 (3.88%) had hospital-onset MRSA infection. The mean age of patients was 76 (SD = 15) years, including 172 (15.18%) aged 20 to 59 years and 961 (84.8%) aged ≥60 years. The annual incidence rates in age groups of 20 to 59 years and ≥60 years were 0.96 to 1.148 per 100 000 and 22.7 to 24.8 per 100 000, respectively. The 30-day mortality was 367 (32.39%). Older patients (>79 years), chronic lung disease, and prior hospitalization were associated with increased mortality. The mean cost was US$10 565 (SD = 11 649; US$1 = HK$7.8). MRSA BSI was a significant burden in Hong Kong.